Aikium

Developer of protein therapeutics intended for neuro-inflammation and oncology. The company leverages breakthroughs in synthetic biology and deep learning to develop proprietary non-antibody scaffold proteins that bind to disordered regions of target proteins in a sequence-specific manner, providing clients with therapeutics to effectively target disordered proteins.